1 / 4

Non-invasive Prenatal Testing (NIPT) Market – Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2018–

Non-invasive prenatal testing is a DNA test on maternal blood to screen pregnancies for the most common fetal chromosome anomalies such as trisomy 21 that is Down syndrome, trisomy 18 Edwards syndrome and trisomy 13 Patau syndrome.<br>

RUSHIKESH
Download Presentation

Non-invasive Prenatal Testing (NIPT) Market – Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2018–

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Non-invasive Prenatal Testing (NIPT) Market – Non-invasive Prenatal Testing (NIPT) Market – Global Industry Insights, Trends, Outlook, and Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2018–2026 Opportunity Analysis, 2018–2026 Non-invasive prenatal testing is a DNA test on maternal blood to screen pregnancies for the most common fetal chromosome anomalies such as trisomy 21 that is Down syndrome, trisomy 18 Edwards syndrome and trisomy 13 Patau syndrome. Whereas NIPT can also determine the gender of the fetus and NIPT is highly reliable in over 99% of Down syndrome cases. The results of the NIPT screening can help doctor to decide the next steps, including whether to have a diagnostic test like chorionic villus sampling (CVS) or collected from the amniotic fluid or placenta, to make sure whether a baby has a chromosome abnormality. Non-invasive prenatal testing can be performed any time after 9 weeks into your pregnancy earlier than any other prenatal screening or diagnostic test. During non-invasive prenatal testing DNA from the mother and fetus is extracted from maternal blood sample and it is recommended for women who have risk factors for having a baby who has a chromosomal condition and this risk factor may include older maternal age or previously given birth to a baby who has Down syndrome, trisomy 13 or trisomy 18. Non-invasive prenatal testing is also recommended if a woman have an Rh negative blood type because if the fetus is Rh positive, mother might produce Rh antibodies after exposure to fetal red blood cells. This is not a concern during a frst pregnancy, but during subsequent pregnancies. These factors are expected to provide major growth traction to the global non-invasive prenatal testing market. Request Sample Copy of Research Report: https://www.coherentmarketinsights.com/insight/request-sample/579 Rise in number of women choosing late pregnancies is expected to fuel the growth of non- invasive prenatal testing market The average maternal age nowadays is increased due to rise in number of working women so the risk of pregnancies has also increased which shows the growth in the market of NIPT. As a woman age the risk of having baby with Down syndrome increase but other factor also play a role, which include the number of existing siblings and how big is the gap between the child and his immediate preceding sibling. As according to Centers for Disease Control and Prevention in year 2016, Down syndrome continues to be the most common chromosomal disorder, as each year about 6000 babies were born with Down syndrome in the U.S.

  2. Whereas, Centers for Disease Control and Prevention also states in 2017 that older mothers are more likely to have a baby afected by Down syndrome than younger mothers. In other words, the prevalence of Down syndrome increases as the mother’s age increases, which is also expected to favor growth of non-invasive prenatal testing market. Report includes chapters which deeply display the following deliverable about industry : • Non-invasive Prenatal Testing (NIPT) Market Research Objective and Assumption • Non-invasive Prenatal Testing (NIPT) Market Purview - Report Description, Executive Summary, and Coherent Opportunity Map (COM) • Non-invasive Prenatal Testing (NIPT) Market Dynamics, Regulations, and Trends Analysis - Market Dynamics, Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST Analysis • Global Non-invasive Prenatal Testing (NIPT) Market, By Regions • Non-invasive Prenatal Testing (NIPT) Market Competition by Manufacturers including Production, Share, Revenue, Average Price, Manufacturing Base Distribution, Sales Area and Product Type. • Non-invasive Prenatal Testing (NIPT) Market Manufacturers Profiles/Analysis including Company Basic Information, Manufacturing Base and Its Competitors. • Non-invasive Prenatal Testing (NIPT) Market Manufacturing Cost Analysis including Key Raw Materials and Key Suppliers of Raw Materials. • Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials Sourcing and Downstream Buyers • Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market Positioning and Distributors/Traders List. • Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer Preference Change and Economic/Political Environmental Change. • Non-invasive Prenatal Testing (NIPT) Market Forecast including Production, Consumption, Import and Export Forecast by Type, Applications and Region. • Research Findings and Conclusion The non-invasive prenatal testing market is driven by product launches and development strategies such as acquisition and collaboration by manufacturers. Recently Sequenom Inc. was acquired by LabCorp in January 2017. Other key players operating the market include GE Healthcare, Koninklijke Philips N.V., Illumina, Inc., Thermo Fisher Scientific, Inc., F. Hoffmann- La Roche Ltd., Pacific Biosciences of California, Inc., PerkinElmer, Inc., QIAGEN N.V., Agilent Technologies, Inc., and Beijing Genomics Institute. Inquire Here Before Purchase: https://www.coherentmarketinsights.com/insight/talk-to-analyst/579

  3. Non-invasive Prenatal Testing Market Taxonomy By Product Type Assay Kits & Reagents Consumables Disposables Next-Generation Sequencing System Instruments PCR Instruments Ultrasound Devices Microarrays Other Instruments • • • • • • • • • By Method Ultrasound Detection Cell-free DNA in Maternal Plasma Tests Biochemical Screening tests Fetal Cells in Maternal Plasma Tests • • • • By Application Trisomy Micro deletion Syndrome Other Application • • • By End User Diagnostic Laboratories Hospitals • • About Coherent Market Insights Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us Mr. Shah Coherent Market Insights

  4. 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: sales@coherentmarketinsights.com

More Related